Back to Browse Journals » Integrated Blood Pressure Control » Volume 4

A critical appraisal of the clinical effectiveness of a fixed combination of valsartan, amlodipine, and hydrochlorothiazide in achieving blood pressure goals

Authors Cheryl L Laffer, Fernando Elijovich

Published 19 January 2011 Volume 2011:4 Pages 1—5

DOI http://dx.doi.org/10.2147/IBPC.S6562

Review by Single-blind

Peer reviewer comments 3

Cheryl L Laffer1, Fernando Elijovich2
1Section of Hypertension and Vascular Medicine, 2Division of General Internal Medicine, Department of Medicine, Texas A&M Health Sciences Center College of Medicine, Temple, TX USA

Abstract: Recent guidelines for the treatment of hypertension have focused on the need for multiple medications to get most patients to goal blood pressure (BP). Two to three different classes of antihypertensive agents are frequently required, increasing the risk of poor compliance with therapy. Hence, the guidelines have recommended starting with combination therapy in patients with BP that is over 20 mm Hg systolic or 10 mm Hg diastolic above goal. The latest advance in treatment regimen has been the development of triple-therapy combinations of an angiotensin receptor blocker, amlodipine, and hydrochlorothiazide. We review the pathophysiologic rationale for such a combination and the efficacy, safety, and tolerability of the first triple therapy that has become available: valsartan + amlodipine + hydrochlorothiazide. Finally, we suggest that use of triple therapy could improve the accuracy of diagnosing resistant hypertension, an increasingly prevalent and severe condition, by enhancing adherence to treatment and weeding out patients with pseudoresistance. This would allow for implementation of expensive and invasive workup only in those truly resistant patients in whom it is justified.

Keywords: combination therapy, compliance, hypertension control rates, resistant hypertension

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 

 

Readers of this article also read:

Management of patients with resistant hypertension: current treatment options

Kumar N, Calhoun DA, Dudenbostel T

Integrated Blood Pressure Control 2013, 6:139-151

Published Date: 22 October 2013

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Long-term use and tolerability of irbesartan for control of hypertension

Forni V, Wuerzner G, Pruijm M, Burnier M

Integrated Blood Pressure Control 2011, 4:17-26

Published Date: 18 April 2011

Optimal management of hypertension in elderly patients

Maria Czarina Acelajado

Integrated Blood Pressure Control 2010, 3:145-153

Published Date: 11 November 2010

Can nocturnal hypertension predict cardiovascular risk?

Oded Friedman, Alexander G Logan

Integrated Blood Pressure Control 2009, 2:25-37

Published Date: 4 September 2009

Antihypertensive effects of astaxanthin

Hidekatsu Yanai, Kumie Ito, Hiroshi Yoshida, Norio Tada

Integrated Blood Pressure Control 2008, 1:1-3

Published Date: 27 October 2008